A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCl in Postmenopausal Women with Metastatic Estrogen Receptor Positive, Her2 Negative Breast Cancer
This randomized phase II trial studies how well tamoxifen citrate works compared with
z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby
tissue or lymph nodes or other parts of the body and has estrogen receptors but not human
epidermal growth factor receptor 2 (HER2) receptors on the surface of its cells. Estrogen can
cause the growth of tumor cells. Hormone therapy using tamoxifen citrate or z-endoxifen
hydrochloride may fight breast cancer by lowering the amount of estrogen the body makes. It
is not yet known whether tamoxifen citrate or z-endoxifen hydrochloride is more effective in
treating patients with breast cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.